UAE Entrepreneur Joins UK Biotech Research Firm Vaxbio as Strategic Advisor to Help Launch Affordable COVID-19 Vaccine | AFN News


Previous story:

The railways are canceling 84 additional trains; 155 trains canceled until March 31 due to coronavirus

Next story:

PM to address nation on COVID-19 outbreak and efforts to combat it

UAE Entrepreneur Joins UK Biotech Research Firm Vaxbio as Strategic Advisor to Help Launch Affordable COVID-19 Vaccine

Posted on March 19, 2020

Dubai: Mr. Khurram Shroff, President of the IBC Group in Dubai, has joined Vaxbio, a biotechnology company based in Oxford, England, as a strategic advisor. Vaxbio is a research and development company that produces affordable vaccines, clones and innovative biologics. Mr. Shroff will advise Vaxbio on development, communicate, execute and support its business initiatives.

As part of its comprehensive portfolio, Vaxbio’s services also extend to research into live viral vaccines. Early access to coronavirus data has helped their experts to sequence and successfully design a vaccine methodology that should help stop and reverse the spread of contagion across the world. The vaccine is already being tested on animals to assess its effectiveness and detect possible side effects that require monitoring. Vaxbio plans to move to clinical 1 and clinical 2 trials as soon as possible, so that the vaccine can be developed and in production by the summer.

Dr Gaurav Gupta, one of the directors of Vaxbio and principal investigator at the Jenner Institute at the University of Oxford, has been active in the research and development of the vaccine. Oxford University, in collaboration with Wuhan University, made significant contributions to the sequencing. Vaxbio had access to the sequencing even before its publication and presented a patent for the COVID-19 (Wuhan Novel Coronavirus 19) vaccine to the UK Patent Office on February 17, 2020.

“Dr Gupta’s research at the University of Oxford gave him rapid access to sequencing the corona virus,” confirmed Dr Shroff. “They have come up with a formulation that will be affordable. It will cost up to (US) 50 cents per dose, which will allow production of the vaccine in batches of 20 million. This will allow us to provide assistance to several countries, nationally, in a week. We should be ready with the vaccine this summer, especially if we are fast-tracked by the UK Patent Office and are sufficiently supported with resources ”.

Among his other healthcare companies, Mr. Shroff recently supported the Medical Resource Acquisition Group, LLC (MRAG), an investment firm focused on disruptive medical technologies, to bring dialysis solutions to the cutting edge technology in the Middle East. East, China and India.

With the latest reports confirming that the coronavirus pandemic has already infected more than 110,000 people, organizations and leaders around the world are coming together to make a difference. Mr Shroff has pledged $ 5 million to help the pharmaceutical industry, doctors and scientists in their efforts to develop an effective vaccination to fight the COVID-19 pandemic. His contribution is in addition to donations from other leading figures in the global business community, such as Alibaba founder Jack Ma, billionaire philanthropist Bill Gates and Hong Kong’s richest man Li Ka-Shing. , who have collectively pledged more than $ 100 billion in efforts to help flatten the curve of this epidemic.


Leave A Reply